Compact Oxygen Generation Medical Devices: Compact Oxygen Generation, Medical (COGM) and Compact Oxygen Generation, Medical – At Altitude (COGM-A)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Health Agency (DHA) has issued a Request for Prototype Proposal (RPP) under Other Transaction Authority (OTA) (10 U.S.C. 4022) for the development of Compact Oxygen Generation Medical Devices (COGM and COGM-A). This initiative seeks expeditionary, easy-to-maintain, and portable medical oxygen generation solutions for service members in austere environments. The goal is to develop FDA-approved prototypes, ideally starting at Technology Readiness Level (TRL) 4. Proposals are due March 6, 2026.
Scope of Work
This RPP focuses on two distinct devices:
- Compact Oxygen Generation, Medical (COGM): High priority, primarily for Role 1 care, with adjustable flow rates (3-7 lpm minimum, 15 lpm desired) for nasal cannulas, face masks, and nebulizers. Target regulatory approval by 2029 and procurement by 2031.
- Compact Oxygen Generation, Medical – At Altitude (COGM-A): For aeromedical evacuation platforms, offering adjustable flow up to 15 lpm and high-pressure output for ventilators. Target regulatory approval by 2030 and procurement by 2032.
The effort involves six core objectives: project management, prototype development/technical design and delivery, manufacturing (cGMP/QMS), regulatory strategy and FDA submissions, maintenance and sustainment planning, and In Progress Reviews (IPR). Devices must meet stringent performance standards, including FDA clearance, specific oxygen purity, size/weight limits (COGM <=24 lbs), power, battery life, operational availability, airworthiness, reliability, interoperability, and maintainability (MIL-STD-810H compliant).
Contract & Timeline
- Type: Request for Prototype Proposal (RPP) under Other Transaction Authority (OTA), potentially resulting in multiple awards.
- Period of Performance: Up to 24 months for COGM development; up to 36 months for COGM-A development. Faster completion is preferred.
- Published Date: January 22, 2026
- Pre-Proposal Meeting Registration Due: January 30, 2026
- RPP Questions Due: February 6, 2026
- Proposals Due: March 6, 2026
Eligibility & Set-Aside
This opportunity is issued under Other Transaction Authority (OTA), which encourages participation from:
- At least one nontraditional defense contractor or nonprofit research institute participating to a significant extent.
- All significant participants being small businesses or nontraditional defense contractors.
- At least one-third of the total project cost being paid by parties other than the Federal Government. Offerors must complete a "Warranties and Representations" attachment to declare their status and contributions. There is no traditional set-aside designation.
Evaluation
Proposals will be evaluated based on three volumes:
- Technical Approach
- Management Approach
- Administrative and Cost
Key Requirements & Attachments
Bidders must submit proposals in three volumes and address critical compliance requirements. Mandatory attachments include a "Prohibition on Contracting with Malign Foreign Talent Programs" certification, a Medical Device and Equipment Risk Assessment (MDERA) Questionnaire, a Software Bill of Materials (SBOM), and detailed cost summary sheets. The Data Item Description (DID) for FDA-regulated products outlines extensive documentation requirements. Offerors must be registered in SAM.gov.